- Home
- UNB vs KLRS Comparison
UNB vs KLRS Comparison
Compare UNB & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNB
- KLRS
- Stock Information
- Founded
- UNB 1891
- KLRS 2019
- Country
- UNB United States
- KLRS United States
- Employees
- UNB N/A
- KLRS N/A
- Industry
- UNB Major Banks
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UNB Finance
- KLRS Health Care
- Exchange
- UNB Nasdaq
- KLRS Nasdaq
- Market Cap
- UNB 159.0M
- KLRS 129.0M
- IPO Year
- UNB 1998
- KLRS N/A
- Fundamental
- Price
- UNB $26.27
- KLRS $2.40
- Analyst Decision
- UNB
- KLRS Buy
- Analyst Count
- UNB 0
- KLRS 1
- Target Price
- UNB N/A
- KLRS N/A
- AVG Volume (30 Days)
- UNB 8.2K
- KLRS 46.4K
- Earning Date
- UNB 07-16-2025
- KLRS 08-15-2025
- Dividend Yield
- UNB 5.53%
- KLRS N/A
- EPS Growth
- UNB N/A
- KLRS N/A
- EPS
- UNB 1.94
- KLRS N/A
- Revenue
- UNB $47,827,000.00
- KLRS N/A
- Revenue This Year
- UNB N/A
- KLRS N/A
- Revenue Next Year
- UNB N/A
- KLRS N/A
- P/E Ratio
- UNB $13.87
- KLRS N/A
- Revenue Growth
- UNB N/A
- KLRS N/A
- 52 Week Low
- UNB $21.00
- KLRS $2.38
- 52 Week High
- UNB $37.70
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- UNB 30.17
- KLRS N/A
- Support Level
- UNB $26.81
- KLRS N/A
- Resistance Level
- UNB $28.71
- KLRS N/A
- Average True Range (ATR)
- UNB 0.64
- KLRS 0.00
- MACD
- UNB -0.14
- KLRS 0.00
- Stochastic Oscillator
- UNB 3.14
- KLRS 0.00
About UNB Union Bankshares Inc.
Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The company provides retail banking services to individuals and commercial banking services to small and medium-sized corporations, partnerships, and sole proprietorships, as well as nonprofit organizations, local municipalities, and school districts within its market area. In addition, it also offers fiduciary and asset management services through its Asset Management Group.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.